CN105164119B - 作为5‑ht4受体激动剂的5‑氨基‑喹啉‑8‑甲酰胺衍生物 - Google Patents
作为5‑ht4受体激动剂的5‑氨基‑喹啉‑8‑甲酰胺衍生物 Download PDFInfo
- Publication number
- CN105164119B CN105164119B CN201380074877.9A CN201380074877A CN105164119B CN 105164119 B CN105164119 B CN 105164119B CN 201380074877 A CN201380074877 A CN 201380074877A CN 105164119 B CN105164119 B CN 105164119B
- Authority
- CN
- China
- Prior art keywords
- quinoline
- amino
- carboxamide
- methyl
- piperidinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1[C@]2C1CC*(*C(C)(C)N)C2 Chemical compound CC1[C@]2C1CC*(*C(C)(C)N)C2 0.000 description 3
- ATAHYKWRFNQZLZ-UHFFFAOYSA-N CC(C)(COS(c1ccc(C)cc1)(=O)=O)O Chemical compound CC(C)(COS(c1ccc(C)cc1)(=O)=O)O ATAHYKWRFNQZLZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1199/CHE/2013 | 2013-03-20 | ||
| IN1199CH2013 IN2013CH01199A (enExample) | 2013-03-20 | 2013-10-18 | |
| PCT/IN2013/000639 WO2014147636A1 (en) | 2013-03-20 | 2013-10-18 | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105164119A CN105164119A (zh) | 2015-12-16 |
| CN105164119B true CN105164119B (zh) | 2017-12-08 |
Family
ID=54325095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380074877.9A Expired - Fee Related CN105164119B (zh) | 2013-03-20 | 2013-10-18 | 作为5‑ht4受体激动剂的5‑氨基‑喹啉‑8‑甲酰胺衍生物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9790211B2 (enExample) |
| EP (1) | EP2976337B1 (enExample) |
| JP (1) | JP6185650B2 (enExample) |
| KR (1) | KR101815307B1 (enExample) |
| CN (1) | CN105164119B (enExample) |
| AP (1) | AP2015008742A0 (enExample) |
| AU (1) | AU2013382944B2 (enExample) |
| BR (1) | BR112015024060A2 (enExample) |
| CA (1) | CA2907620C (enExample) |
| DK (1) | DK2976337T3 (enExample) |
| EA (1) | EA029365B1 (enExample) |
| ES (1) | ES2674993T3 (enExample) |
| IN (1) | IN2013CH01199A (enExample) |
| MX (1) | MX364929B (enExample) |
| NZ (1) | NZ712369A (enExample) |
| SG (1) | SG11201507763RA (enExample) |
| WO (1) | WO2014147636A1 (enExample) |
| ZA (1) | ZA201506804B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107406434B (zh) * | 2015-02-13 | 2020-09-11 | 苏文生命科学有限公司 | 作为5-ht4受体激动剂的酰胺化合物 |
| CN109444301A (zh) * | 2018-12-18 | 2019-03-08 | 江苏省中医院 | 一种测定血浆中普芦卡必利浓度的方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1092772A (zh) * | 1992-10-13 | 1994-09-28 | 史密丝克莱恩比彻姆有限公司 | 药物 |
| FR2756564A1 (fr) * | 1996-12-04 | 1998-06-05 | Synthelabo | Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique |
| WO2001095902A1 (en) * | 2000-06-15 | 2001-12-20 | Respiratorius Ab | A composition comprising a combination of receptor agonists and antagonists |
| WO2007068739A1 (en) * | 2005-12-16 | 2007-06-21 | Glaxo Group Limited | 4-amino-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, neurological and cardiovascular disorders |
| CN102753172A (zh) * | 2010-02-12 | 2012-10-24 | 拉夸里亚创药株式会社 | 用于治疗痴呆的5-ht4受体激动剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705498A (en) | 1992-11-05 | 1998-01-06 | Smithkline Beecham Plc. | Piperidine derivatives as 5-HT4 receptor antagonists |
| ATE373651T1 (de) * | 2003-06-19 | 2007-10-15 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidinbenzamide als 5ht4- antagonisten |
| EP1689742B1 (en) | 2003-11-24 | 2010-03-17 | Pfizer, Inc. | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
| ES2340855T3 (es) | 2003-12-23 | 2010-06-10 | Serodus As | Modulares de receptores 5-ht perifericos. |
| WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| JP4970290B2 (ja) | 2005-02-25 | 2012-07-04 | ファイザー株式会社 | ベンズイソキサゾール誘導体 |
| JP5075818B2 (ja) | 2005-07-22 | 2012-11-21 | ファイザー株式会社 | ５ｈｔ４受容体アゴニストとしてのインダゾールカルボキサミド誘導体 |
| AU2011216950A1 (en) | 2010-02-16 | 2012-08-23 | Pfizer Inc. | (R)-4-((4-((4-(tetrahydrofuran-3-yloxy) benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, a partial agonist of 5-HT4 receptors |
-
2013
- 2013-10-18 MX MX2015012350A patent/MX364929B/es active IP Right Grant
- 2013-10-18 JP JP2016504852A patent/JP6185650B2/ja not_active Expired - Fee Related
- 2013-10-18 AP AP2015008742A patent/AP2015008742A0/xx unknown
- 2013-10-18 AU AU2013382944A patent/AU2013382944B2/en not_active Ceased
- 2013-10-18 BR BR112015024060A patent/BR112015024060A2/pt not_active IP Right Cessation
- 2013-10-18 KR KR1020157030158A patent/KR101815307B1/ko not_active Expired - Fee Related
- 2013-10-18 WO PCT/IN2013/000639 patent/WO2014147636A1/en not_active Ceased
- 2013-10-18 NZ NZ712369A patent/NZ712369A/en not_active IP Right Cessation
- 2013-10-18 SG SG11201507763RA patent/SG11201507763RA/en unknown
- 2013-10-18 EP EP13811624.9A patent/EP2976337B1/en active Active
- 2013-10-18 CN CN201380074877.9A patent/CN105164119B/zh not_active Expired - Fee Related
- 2013-10-18 CA CA2907620A patent/CA2907620C/en not_active Expired - Fee Related
- 2013-10-18 EA EA201591844A patent/EA029365B1/ru not_active IP Right Cessation
- 2013-10-18 ES ES13811624.9T patent/ES2674993T3/es active Active
- 2013-10-18 US US14/777,925 patent/US9790211B2/en not_active Expired - Fee Related
- 2013-10-18 DK DK13811624.9T patent/DK2976337T3/en active
- 2013-10-18 IN IN1199CH2013 patent/IN2013CH01199A/en unknown
-
2015
- 2015-09-14 ZA ZA2015/06804A patent/ZA201506804B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1092772A (zh) * | 1992-10-13 | 1994-09-28 | 史密丝克莱恩比彻姆有限公司 | 药物 |
| FR2756564A1 (fr) * | 1996-12-04 | 1998-06-05 | Synthelabo | Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique |
| WO2001095902A1 (en) * | 2000-06-15 | 2001-12-20 | Respiratorius Ab | A composition comprising a combination of receptor agonists and antagonists |
| WO2007068739A1 (en) * | 2005-12-16 | 2007-06-21 | Glaxo Group Limited | 4-amino-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, neurological and cardiovascular disorders |
| CN102753172A (zh) * | 2010-02-12 | 2012-10-24 | 拉夸里亚创药株式会社 | 用于治疗痴呆的5-ht4受体激动剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201591844A1 (ru) | 2016-08-31 |
| BR112015024060A2 (pt) | 2017-07-18 |
| ZA201506804B (en) | 2016-07-27 |
| AU2013382944A1 (en) | 2015-10-08 |
| MX364929B (es) | 2019-05-14 |
| WO2014147636A1 (en) | 2014-09-25 |
| SG11201507763RA (en) | 2015-10-29 |
| EP2976337B1 (en) | 2018-05-02 |
| US20160280694A1 (en) | 2016-09-29 |
| KR101815307B1 (ko) | 2018-01-04 |
| WO2014147636A8 (en) | 2014-12-04 |
| AP2015008742A0 (en) | 2015-09-30 |
| MX2015012350A (es) | 2016-05-09 |
| CA2907620C (en) | 2018-03-13 |
| JP6185650B2 (ja) | 2017-08-23 |
| CA2907620A1 (en) | 2014-09-25 |
| IN2013CH01199A (enExample) | 2015-08-14 |
| US9790211B2 (en) | 2017-10-17 |
| NZ712369A (en) | 2016-11-25 |
| DK2976337T3 (en) | 2018-07-16 |
| EA029365B1 (ru) | 2018-03-30 |
| KR20160004274A (ko) | 2016-01-12 |
| HK1217483A1 (zh) | 2017-01-13 |
| ES2674993T3 (es) | 2018-07-05 |
| CN105164119A (zh) | 2015-12-16 |
| AU2013382944B2 (en) | 2016-08-04 |
| EP2976337A1 (en) | 2016-01-27 |
| JP2016516089A (ja) | 2016-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107406434B (zh) | 作为5-ht4受体激动剂的酰胺化合物 | |
| AU2012309556B2 (en) | Pyrrolidine-3-ylacetic acid derivative | |
| EP3099675B1 (en) | Indazole compounds as 5-ht4 receptor agonists | |
| CN105164119B (zh) | 作为5‑ht4受体激动剂的5‑氨基‑喹啉‑8‑甲酰胺衍生物 | |
| US20230002366A1 (en) | Indene derivatives useful in treating pain and inflammation | |
| HK1217483B (en) | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists | |
| HK1241363B (zh) | 作为5-ht4受体激动剂的酰胺化合物 | |
| TW202539657A (zh) | 雙環酪胺酸激酶２抑制劑及其用途 | |
| WO2003078441A1 (en) | Aminomethyl-substituted thiazolobenzimidazole derivative | |
| HK1241363A1 (en) | Amide compounds as 5-ht4 receptor agonists | |
| WO2014112492A1 (ja) | 新規なオクタヒドロキノリン誘導体、それを含有する医薬組成物およびそれらの用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1217483 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1217483 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171208 Termination date: 20201018 |